NOTCH1 and acute lymphoblastic leukemia: Overall, GSI monotherapy appears insufficient in NOTCH1-mutated T-ALL, while combination regimens represent a promising approach to improve therapeutic outcomes and minimize gastrointestinal toxicity [126].